Prolonged monitoring after propranolol use for infantile haemangioma does not predict adverse events
Repeated vital sign monitoring for initiation and escalation of oral propranolol has seldomly led to a change in management of infantile haemangioma and is not predictive of future adverse events, results of a recent study have shown. Serious adverse events occurring during therapy are few, of which none are cardiovascular.
